Homburger acts as counsel to SIX Group in connection with the contemplated acquisition of Aquis Exchange, which was announced on November 11, 2024. SIX Group operates a fully integrated exchange value chain across the Swiss and Spanish
Tags :Benjamin Leisinger
Homburger advised HANetf ETC Securities plc on the listing of its Responsibly Sourced Physical Gold ETP. Homburger’s team Homburger advised HANetf ETC Securities plc on this transaction with respect to aspects of Swiss law
Homburger has advised the Joint-Lead Managers (UBS Investment Bank, Deutsche Bank AG, J.P. Morgan, and Natixis) on Swiss Life Finance II AG’s successful issuance of EUR 500 million callable subordinated capital securities, with a
On September 18, 2024, Sulzer successfully priced the offering of its CHF 250 million 1.7725% bonds. Homburger acted as counsel to Sulzer with a team consisting of Benjamin Leisinger and Eduard De Zordi (both capital markets). About the bond
Homburger acted as counsel to Raiffeisen Schweiz Genossenschaft, which on September 3 2024, successfully issued EUR 500 million 3.852 per cent. 8NC7 Fixed-to-Fixed Rate Bail-in Bonds due 2032. Deutsche Bank, J.P. Morgan, Morgan Stanley, Raiffeisen Schweiz Genossenschaft and UBS
On May 30, 2024, St.Galler Kantonalbank (Sgkb) successfully issued CHF 200m 2.4% Tier 2 bonds due 2034. Zürcher Kantonalbank (Zkb) acted as sole lead manager and Sgkb as co-manager. Homburger’s team Homburger acted as counsel to Zkb
The Swiss special purpose issuance vehicle Xtrackers Digital Markets ETC AG, simultaneously launched two series of crypto-linked Exchange Traded Products (ETPs). This falls under its program for the issuance of cryptocurrency-focused ETPs for professional and
Stiftung PWG has successfully launched and priced its issuance of CHF 120 million total nominal amount of 1.55% Sustainability Bonds 2024-2032. Stiftung PWG is an institution under public law the purpose of which is to maintain or
The American supplier of analytical instruments, Thermo Fisher Scientific, with annual revenues of close to US$50 billion, has successfully completed the issuance of its inaugural Swiss franc bonds. It is reportedly the largest foreign Swiss
AC Immune, a Swiss clinical stage biopharmaceutical company pioneering in precision medicine for neurodegenerative diseases listed on the Nasdaq completed an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per
